NCT03328130View on ClinicalTrials.gov

Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

November 6, 2017

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions

Retinitis Pigmentosa

Interventions

BIOLOGICAL

AAV2/5-hPDE6B

Subretinal administration in one eye

Trial Locations (1)

44093

RECRUITING

Clinique Ophtalmologique, CHU de Nantes, Nantes

All Listed Sponsors

lead

eyeDNA Therapeutics

INDUSTRY